PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Journal of Clinical Psychiatry and Clinical Neuroscience

1 Papers Indexed in Blossom

Data updated October 28, 2025

Research Footprint

Journal of Clinical Psychiatry and Clinical Neuroscience has 1 tracked paper indexed in Blossom (2023) from 8 authors, across Tobacco/Nicotine Use Disorder (TUD), Substance Use Disorders (SUD) and Neurological Injury.

Published Papers

Paywallindividual

Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results

This survey study (n=980) assessed the perspectives of patients with functional neurological disorders (FND) (e.g. multiple sclerosis, stroke) on novel treatments like psychedelic therapoy. 15% of respondents reported using illicit substances to manage their symptoms, with the majority expereincing no or minimal physical and psychological sequale. 46% of respondents reported that they would be willing to try medically supervised psychedelic therapy.

Published
January 1, 2023
Journal
Journal of Clinical Psychiatry and Clinical Neuroscience
Authors
Butler, M., Seynaeve, M., Bao, J., Crawshaw, A., Pick, S., Nicholson, T. R., Rucker, J., Bradley-Westgaurd, A.

Quick Facts

Papers Indexed
1
Publisher
Pulsus Group
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.